Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21580172 | 0.89 | HPGD (0.62) | LMNAHPGDSMN1; SMN2MAPK8KMT2A | |
| SCHEMBL30989915 | 0.86 | LMNA (0.80) | LMNAHPGDSMN1; SMN2MAPK8KMT2A | |
| SCHEMBL1681273 | 0.85 | SCN3A (0.56) | LMNAHPGDSMN1; SMN2MAPK8SCN3A | |
| SCHEMBL21580137 | 0.79 | SCN3A (0.54) | LMNASMN1; SMN2SCN3ASCN9AKMT2A | |
| SCHEMBL18715343 | 0.79 | HPGD (0.79) | LMNAHPGDSMN1; SMN2MAPK8KMT2A | |
| SCHEMBL8373056 | 0.79 | HPGD (0.72) | LMNAHPGDSMN1; SMN2MAPK8KMT2A | |
| SCHEMBL21580115 | 0.78 | SCN3A (0.50) | LMNASCN3ASCN9AMAPT | |
| SCHEMBL21580123 | 0.78 | TSHR (0.57) | LMNAHPGDSMN1; SMN2SCN3ASCN9A | |
| SCHEMBL921387 | 0.78 | RORC (0.61) | LMNAHPGDSMN1; SMN2MAPK8KMT2A | |
| SCHEMBL21580164 | 0.78 | SCN3A (0.52) | LMNAHPGDSMN1; SMN2SCN3ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2021-07-29 | — | — | US | disclosed |
| WO-2019218024-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2019-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230157-A1 | PAIN TREATING COMPOUNDS AND USES THEREOF | TRPV1, TRPA1, TRPV3 | LMNA 2438/4885HPGD 521/4885SMN1; SMN2 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.